SOURCE: INSYS Therapeutics

Insys Therapeutics

January 05, 2015 08:00 ET

Insys Therapeutics to Present at 33rd Annual J.P. Morgan Healthcare Conference

PHOENIX, AZ--(Marketwired - Jan 5, 2015) - Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference as follows:

Conference: Wednesday, January 14, 2015
Time: 3:00 p.m. PST
Location: The Westin St. Francis Hotel, San Francisco, California

The presentation will be webcast live at the aforementioned time as well as archived for 90 days thereafter, via the Company's website at www.insysrx.com, under the Investors Section.

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. Insys is also developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

Subsys® is a registered trademark of Insys Therapeutics, Inc.